Literature DB >> 3924609

Reaction of antibody in sera from cystic fibrosis patients with non-toxic forms of Pseudomonas aeruginosa exotoxin A.

K W Klinger, C W Shuster, J Klinger.   

Abstract

Sera from 48 cystic fibrosis patients from two hospitals were screened for antibody against rods, non-toxic macromolecular structures which share antigenic determinants with Pseudomonas aeruginosa exotoxin A. A solid-phase radioimmunoassay employing (125I)-staphylococcal protein A was used to detect anti-rod IgG. Antibodies recognizing rods, exotoxin A, or both antigens, were demonstrated using a competitive radioimmunoassay in cystic fibrosis patient sera, and in sera from animals immunized with exotoxin A, rods, or infected with Pseudomonas aeruginosa. Anti-rod titers of cystic fibrosis patients (1.07 to 14 X control serum levels) inversely correlated with aggregate clinical evaluation scores, and in most instances, with X-ray scores. Since rods are non-toxic and cross-reactive with exotoxin A, they may represent therapeutically useful antigens for producing immunity to exotoxin A.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924609     DOI: 10.1007/BF02013598

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   5.103


  22 in total

1.  A 5 YEAR CLINICAL EVALUATION OF A THERAPEUTIC PROGRAM FOR PATIENTS WITH CYSTIC FIBROSIS.

Authors:  C F DOERSHUK; L W MATTHEWS; A S TUCKER; H NUDLEMAN; G EDDY; M WISE; S SPECTOR
Journal:  J Pediatr       Date:  1964-11       Impact factor: 4.406

Review 2.  Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1977

3.  Quantitation and identification of antibodies to outer-membrane proteins of Pseudomonas aeruginosa in sera of patients with cystic fibrosis.

Authors:  R E Hancock; E C Mouat; D P Speert
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

4.  Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.

Authors:  J D Klinger; D C Straus; C B Hilton; J A Bass
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

5.  Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

Authors:  G Döring; N Høiby
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

6.  Hypogammaglobulinemia in patients with cystic fibrosis.

Authors:  W J Matthews; M Williams; B Oliphint; R Geha; H R Colten
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

7.  Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.

Authors:  J D Klinger; H A Cash; R E Wood; J J Miler
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.

Authors:  O R Pavlovskis; D C Edman; S H Leppla; B Wretlind; L R Lewis; K E Martin
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.609

9.  Detection by enzyme-linked immunosorbent assays of antibody specific for Pseudomonas proteases and exotoxin A in sera from cystic fibrosis patients.

Authors:  K S Jagger; D L Robinson; M N Franz; R L Warren
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 11.677

10.  Clinical significance of serum antibody responses to exotoxin A and type-specific lipopolysaccharides in patients with Pseudomonas aeruginosa infections.

Authors:  M Pollack; R N Longfield; W W Karney
Journal:  Am J Med       Date:  1983-06       Impact factor: 5.928

View more
  1 in total

1.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.